Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapy. Found 482 abstracts

no pagination
Bleicher RJ. Reply to E.A. Peralta et al. J Clin Oncol. 2014 Sep;32(25):2818-9.
Bleicher RJ, Topham NS, Morrow M. Reply to letter: "Anaplastic large cell lymphomas and breast implants". Ann Surg. 2014 Jan;259(1):e5.   PMCID: Letter
Chera BS, Eisbruch A, Murphy BA, Ridge JA, Gavin P, Reeve BB, Bruner DW, Movsas B. Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. Journal of the National Cancer Institute. 2014 Jul;106(7).   PMCID: 4192043
Fleisher L, Ruggieri DG, Miller SM, Manne S, Albrecht T, Buzaglo J, Collins MA, Katz M, Kinzy TG, Liu T, Manning C, Charap ES, Millard J, Miller DM, Poole D, Raivitch S, Roach N, Ross EA, Meropol NJ. Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) study. Patient education and counseling. 2014 Jul;96(1):63-71.   PMCID: PMC4171039
Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014 Jan;10(11):3415-24.   PMCID: PMC4514043
Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014 Dec;18(101):341-50.
Handorf EA, Smaldone MC. Editorial comment. Urology. 2014 Jan;83(1):132-3; discussion 133.   PMCID: Editorial
Hasan N, Kumar R, Kavuru MS. Lung cancer screening beyond low-dose computed tomography: the role of novel biomarkers. Lung. 2014 Oct;192(5):639-48.
Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. Journal of the National Cancer Institute. 2014 May;106(5).   PMCID: 4112926
Johnson ME, Handorf EA, Martin JM, Hayes SB. Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer. 2014 Nov 15;120(22):3569-74.   PMCID: 4413466
Johnson ME, Robu VG, Turaka A. Nasopharyngeal Hodgkin lymphoma. J Clin Oncol. 2014 Apr 10;32(11):e40-1.
Johnson ME, Zhu F, Li T, Wu H, Galloway TJ, Farma JM, Perlis CS, Turaka A. Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma. J Am Acad Dermatol. 2014 Jun;70(6):1028-35.   PMCID: No NIH funding
Kim SP, Gross CP, Nguyen PL, Smaldone MC, Shah ND, Karnes RJ, Thompson RH, Han LC, Yu JB, Trinh QD, Ziegenfuss JY, Sun M, Tilburt JC. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care. 2014 Jul;52(7):579-85.
Moul JW, Chen DY, Trabulsi EJ, Warlick CA, Ruckle HC, Porter JR, Yoshida JS, Adams GW, Kella N, Matsunaga GS, Bans LL, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA, investigators of the ProsVue Field Experience T. Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Sep;17(3):280-5.
Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02. Clinical Cancer Research. 2014 Dec;20(24):6379-88.   PMCID: 4299458
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun;20(11):3023-32.   PMCID: Pmc4049169
Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. ACR Appropriateness Criteria(R) thyroid carcinoma. Oral Oncol. 2014 Jun;50(6):577-86.
Siddiqui UD, Barth BA, Banerjee S, Bhat YM, Chauhan SS, Gottlieb KT, Konda V, Maple JT, Murad FM, Pfau P, Pleskow D, Tokar JL, Wang A, Rodriguez SA. Devices for the endoscopic treatment of hemorrhoids. Gastrointestinal endoscopy. 2014 Jan;79(1):8-14.
Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. Journal of hematology & oncology. 2014 Sep;7:58.   PMCID: 4172963
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol. 2014 Nov;192(5):1349-54.   PMCID: PMC4422495
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapy

therapy Female methods Middle Aged Male pathology Aged therapeutic use mortality Prognosis Adult Neoplasm Staging diagnosis Neoplasms Immunotherapy Clinical Trials as Topic immunology 80 and over Aged Proportional Hazards Models Breast Neoplasms metabolism Prostatic Neoplasms Tumor Biomarkers Local Neoplasm Recurrence Antineoplastic Agents Prostatectomy blood United States Monoclonal Antibodies Decision Making Antineoplastic Combined Chemotherapy Protocols Disease-Free Survival Combined Modality Therapy adverse effects secondary Retrospective Studies Neoplasm Invasiveness Treatment Outcome Time Factors Neoplasm Grading Mastectomy Magnetic Resonance Imaging Kidney Neoplasms Laser Coagulation Sclerotherapy Proto-Oncogene Proteins c-akt Kaplan-Meier Estimate Decision support tools Cost-Benefit Analysis US Food and Drug Administration Rbl Cancer Vaccines Ligation Bone Neoplasms Anaplastic thyroid cancer Immunoassay cystectomy ultrasonography Lymphoma X-Ray Computed Tomography Infrared Rays Lung Neoplasms health care Trismus Biological Markers skin neoplasm Quality of Health Care Cryosurgery Alta aluminum potassium sulfate and tannic acid Cancer Cystectomy Skin Neoplasms Thyroid cancer Hemorrhoids epidemiology rubber band ligation Chemoradiotherapy Survival Analysis Head and Neck radiation therapy Questionnaires Differential Diagnosis surgery Multivariate Analysis Patient-Centered Care Well differentiated thyroid cancer radiography hospitals quality indicators Early Detection of Cancer Sialorrhea Irc CTLA-4 Antigen Merkel Cell Carcinoma SEER Program Clinical Decision Support Systems immune function infrared coagulation Diathermy breast cancer Fda High-Intensity Focused Ultrasound Ablation Young Adult Follow-Up Studies Hospitals Hoarseness Paclitaxel ras Proteins genetics etiology Decision Support Techniques Radiation Oncology Patient Education as Topic Phosphatidylinositol 3-Kinases Benchmarking adverse Merkel cell carcinoma physiopathology Lung Phase III Clinical Trials as Topic Urinary Bladder Neoplasms statistics & numerical data Decision aids Deglutition Disorders effects Doppler-guided laser photocoagulation Smooth Muscle Adolescent Neoplasm Drug Resistance Predictive Value of Tests postmastectomy Patient Participation Retreatment Patient Care Team absolute lymphocyte count Androgen Antagonists Hodgkin Disease National Cancer Institute (US) instrumentation Consensus Watchful Waiting Carboplatin Cytokines economics Perception Quality of Life skin cancer organization & administration physiology
Last updated on Friday, January 03, 2020